First Tracks Biotherapeutics, Inc.
TRAX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TRAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TRAX
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases, with lead candidates ANB033 and ANB101 targeting plasmacytoid dendritic cells.
Key risk: No approved products or revenue
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for First Tracks Biotherapeutics, Inc..
Similar companies
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases, with lead candidates ANB033 and ANB101 targeting plasmacytoid dendritic cells.
- First Tracks is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics modulating key nodes of autoimmunity and inflammation [sec · filed 2026-05-08].
- As of June 30, 2026, the company reported cash and equivalents of $168.0M, net income of -$33.4M, and shareholders' equity of $391.6M [sec].
- Lead product candidate ANB033 is being developed for indications including CeD (Celiac disease) and EoE (Eosinophilic esophagitis), with approximately $50 million allocated for continued clinical trials through Phase 1b development [sec · filed 2026-05-08].
- ANB101 is a preclinical-stage antibody targeting pDC depletion, with preclinical data suggesting it is more potent and has a longer half-life compared to litifilimab [sec_mda · as of 2026-08-12].
- The company has no approved products and has not generated any revenue from product sales, relying on its cash position to fund operations [sec · filed 2026-05-08].
What works
- First Tracks has a focused portfolio of immunology therapeutics targeting large, underserved patient populations in gastroenterology, rheumatology, dermatology, and respiratory [sec · filed 2026-05-08].
- ANB101 preclinical data suggests it is a more potent antibody compared to litifilimab with a longer half-life, potentially offering deeper and more durable pDC depletion [sec_mda · as of 2026-08-12].
- The company has a clear strategy to generate translational and clinical data to differentiate its molecules from in-class competitors and standard of care [sec · filed 2026-05-08].
What to weigh
- First Tracks has no approved products and has not generated any revenue from product sales, with a history of operational losses [sec · filed 2026-05-08].
- The company expects to require additional capital to finance operations, and such capital may not be available on acceptable terms, which could delay or prevent development of product candidates [sec · filed 2026-05-08].
- As a clinical-stage company, First Tracks faces significant uncertainty in the timing and cost of clinical trials, regulatory approvals, and commercialization [sec · filed 2026-05-08].
From the filings
Quoted directly from source documents.
First Tracks is a clinical-stage biotechnology company focused on immunology therapeutics.
“We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics.”
SEC filings · May 8, 2026
ANB101 preclinical data suggests it is more potent and has a longer half-life than litifilimab.
“ANB101 preclinical data suggests it is a more potent antibody compared to litifilimab with a longer half-life that results in a deeper and more durable PD effect on pDC depletion.”
SEC MD&A · August 12, 2026
The company has no approved products and no revenue from product sales.
“We have no products approved for commercial sale, and to date we have not generated any revenue or profit from sales of our product candidates.”
SEC filings · May 8, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — First Tracks has no approved products and has not generated any revenue from product sales, relying entirely on its cash position [sec · filed 2026-05-08].
- Need for additional capital — The company expects to require additional capital to finance operations, which may not be available on acceptable terms [sec · filed 2026-05-08].
- Clinical development uncertainty — The timing, cost, and outcome of clinical trials for ANB033 and ANB101 are uncertain, with risk of failure [sec · filed 2026-05-08].
- Reliance on lead candidates — Focus on ANB033 and ANB101 may cause the company to forego other opportunities that could have greater commercial potential [sec · filed 2026-05-08].
What to watch
- Progress of ANB033 through Phase 1b clinical trials in CeD and EoE, with $50 million allocated for this development [sec · filed 2026-05-08].
- Initiation and results of ANB101 Phase 1a clinical trials, with $5 million allocated for this development [sec · filed 2026-05-08].
- Cash runway and any future capital raises, as the company expects to need additional funding [sec · filed 2026-05-08].
- Regulatory updates and clinical data readouts that could impact the valuation and development timeline [sec_mda · as of 2026-08-12].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run First Tracks Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available First Tracks Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
16.1 months
D/E 0.09 · 0% dilution
No tracked pipeline phase
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for First Tracks Biotherapeutics, Inc.?
First Tracks Biotherapeutics, Inc. (TRAX) is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases, with lead candidates ANB033 and ANB101 targeting plasmacytoid dendritic cells.
Who is the CEO of First Tracks Biotherapeutics, Inc.?
Mr. Daniel R. Faga is the chief executive officer of First Tracks Biotherapeutics, Inc. (TRAX).
Where is First Tracks Biotherapeutics, Inc. headquartered?
First Tracks Biotherapeutics, Inc. (TRAX) is headquartered in San Diego, CA, United States.
What therapeutic areas does First Tracks Biotherapeutics, Inc. focus on?
First Tracks Biotherapeutics, Inc. develops therapies across Immunology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.